Squarepoint’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $267M | Buy |
290,181
+80,448
| +38% | +$81.6M | 0.31% | 35 |
|
|
2025
Q4 | $225M | Sell |
209,733
-244,025
| -54% | -$233M | 0.24% | 70 |
|
|
2025
Q3 | $346M | Buy |
453,758
+41,865
| +10% | +$31.2M | 0.35% | 40 |
|
|
2025
Q2 | $321M | Buy |
411,893
+375,948
| +1,046% | +$292M | 0.33% | 40 |
|
|
2025
Q1 | $29.7M | Sell |
35,945
-173,815
| -83% | -$145M | 0.04% | 521 |
|
|
2024
Q4 | $162M | Buy |
209,760
+112,390
| +115% | +$93.1M | 0.16% | 93 |
|
|
2024
Q3 | $86.3M | Buy |
97,370
+45,339
| +87% | +$40.8M | 0.13% | 127 |
|
|
2024
Q2 | $47.1M | Buy |
52,031
+15,833
| +44% | +$12.7M | 0.08% | 258 |
|
|
2024
Q1 | $28.2M | Sell |
36,198
-76,590
| -68% | -$54.5M | 0.05% | 465 |
|
|
2023
Q4 | $65.7M | Buy |
112,788
+43,845
| +64% | +$25.6M | 0.12% | 159 |
|
|
2023
Q3 | $37M | Sell |
68,943
-25,890
| -27% | -$13.3M | 0.09% | 244 |
|
|
2023
Q2 | $44.5M | Buy |
+94,833
| New | +$39.8M | 0.14% | 155 |
|
|
2023
Q1 | – | Sell |
-115,448
| Closed | -$38.9M | – | 3528 |
|
|
2022
Q4 | $42.2M | Buy |
115,448
+27,165
| +31% | +$9.63M | 0.17% | 114 |
|
|
2022
Q3 | $28.5M | Buy |
88,283
+33,261
| +60% | +$10.5M | 0.14% | 142 |
|
|
2022
Q2 | $17.8M | Buy |
55,022
+46,172
| +522% | +$13.9M | 0.1% | 224 |
|
|
2022
Q1 | $2.53M | Sell |
8,850
-13,702
| -61% | -$3.53M | 0.01% | 1012 |
|
|
2021
Q4 | $6.23M | Buy |
22,552
+7,065
| +46% | +$1.79M | 0.02% | 704 |
|
|
2021
Q3 | $3.58M | Sell |
15,487
-66,923
| -81% | -$16.5M | 0.01% | 929 |
|
|
2021
Q2 | $18.9M | Buy |
82,410
+14,205
| +21% | +$2.85M | 0.07% | 251 |
|
|
2021
Q1 | $12.7M | Sell |
68,205
-23,796
| -26% | -$4.65M | 0.07% | 296 |
|
|
2020
Q4 | $15.5M | Sell |
92,001
-218,948
| -70% | -$32.7M | 0.12% | 158 |
|
|
2020
Q3 | $46M | Buy |
310,949
+191,427
| +160% | +$29.6M | 0.62% | 18 |
|
|
2020
Q2 | $19.6M | Buy |
+119,522
| New | +$18.3M | 0.32% | 45 |
|
|
2019
Q4 | – | Sell |
-148,729
| Closed | -$17.2M | – | 2657 |
|
|
2019
Q3 | $16.6M | Buy |
148,729
+37,889
| +34% | +$4.22M | 0.15% | 168 |
|
|
2019
Q2 | $12.3M | Buy |
110,840
+107,709
| +3,440% | +$12.7M | 0.12% | 210 |
|
|
2019
Q1 | $406K | Sell |
3,131
-38,569
| -92% | -$4.69M | ﹤0.01% | 1592 |
|
|
2018
Q4 | $4.83M | Sell |
41,700
-132,504
| -76% | -$14.8M | 0.06% | 418 |
|
|
2018
Q3 | $18.7M | Buy |
+174,204
| New | +$17.4M | 0.22% | 112 |
|
|
2018
Q2 | – | Sell |
-80,800
| Closed | -$6.25M | – | 1919 |
|
|
2018
Q1 | $6.25M | Sell |
80,800
-67,620
| -46% | -$5.44M | 0.1% | 262 |
|
|
2017
Q4 | $12.5M | Buy |
+148,420
| New | +$12.6M | 0.22% | 92 |
|
|
2017
Q3 | – | Sell |
-81,737
| Closed | -$6.73M | – | 1758 |
|
|
2017
Q2 | $6.73M | Buy |
+81,737
| New | +$6.67M | 0.13% | 197 |
|
|
2016
Q2 | – | Sell |
-105,253
| Closed | -$7.58M | – | 1241 |
|
|
2016
Q1 | $7.58M | Buy |
+105,253
| New | +$7.96M | 0.59% | 15 |
|
|
2015
Q2 | – | Sell |
-3,340
| Closed | -$243K | – | 540 |
|
|
2015
Q1 | $243K | Buy |
+3,340
| New | +$238K | 0.08% | 337 |
|
Other funds holding LLY
VCM
VPM
Squarepoint's LLY Position: Q1 2026 in Review
Squarepoint increased its Eli Lilly (LLY) stake by 38% in Q1 2026, buying an estimated $81.6M and bringing the position to 290,181 shares worth $267M. The position accounts for 0.31% of the portfolio, ranked #35.
Squarepoint first reported a position in LLY in Q1 2015 and has held it in 33 quarters since. The position peaked at $346M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Squarepoint held 290,181 shares of Eli Lilly worth $267M as of Q1 2026.
- Squarepoint bought 80,448 Eli Lilly shares in Q1 2026, an estimated $81.6M.
- Eli Lilly made up 0.31% of Squarepoint's portfolio in Q1 2026, its #35 holding.
- Squarepoint first reported a position in Eli Lilly in Q1 2015 and has held it in 33 quarters since.
- Squarepoint's Eli Lilly position peaked at $346M in Q3 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.